Waldenström Makroglobulinemi: Olgu Temelli Klinik Yaklaşım
Özet
Waldenströmmakroglobulinemi (WM), IgM monoklonal gammopatisi ve kemik iliğinde lenfoplazmasitik infiltrasyon ile karakterize nadir görülen indolent B hücreli neoplazilerden biridir.(1) Klinik spektrum asemptomatik olgulardan hiperviskozite sendromu, sitopeniler ve nörolojik komplikasyonlara kadar geniş bir yelpazede değişkenlik gösterir. Bu yazıda WM’nin doğal seyri ve klinik heterojenitesini yansıtan, asemptomatik fazdan semptomatik evreye ilerleyen entegre bir olgu sunulmuş ve tanı-tedavi yaklaşımı güncel kılavuzlar eşliğinde tartışılmıştır.
Referanslar
K Badurova, J Gregorova, M Vlachova et al. KlinOncol. Waldenströmmacroglobulinemia. 2021 Fall; 34 (6): 428-433. Doi:10.48095/ccko2021428
PrashantKapoor, S Vincent Rajkumar.CurrentapproachtoWaldenströmmacroglobulinemia. Blood Rev. 2023 Nov: 62:101129. Doi:10.1016/j.blre.2023.101129 Epub 2023 Aug 26.
Sigurdur Y Kristinsson, Jill Koshiol, MagnusBjörkholm et al. Immune-relatedandinflammatoryconditionsand risk of lymphoplasmacyticlymphomaorWaldenstrommacroglobulinemia. J NatlCancerInst. 2010 Apr 21; 102 (8):557-67. Doi: 10.1093/jnci/djg043. Epub 2010 Feb 24
Mary L McMaster. Theepidemiology of Waldenströmmacroglobulinemia. Semin Hematol.2023 Mar; 60(2):65-72. Doi: 10.1053/j.seminhematol.2023.03.008. Epub 2023 Mar 31.
Rohan Bir Singh, SachiSinghal, ShrutiSinha et al. Ocularcomplications of plasmacelldyscrasias. Eur J Ophtalmol. 2023 Sep;33(5):1786-1800.doi:10.1177/11206721231155974. Epub 2023 Feb 9
Carlo Canepa. Waldenstrom-associated anti-MAC paraproteinpolyneuropathywithneurogenic tremor. BMJ Case Rep. 2019 Mar 31; 12(3): e228376. Doi:10.1136/bcr-2018-228376
ShahrzadJalali, Stephen M Ansell. The Bone MarrowMicroenvironment in WaldenströmMacroglobulinemia. HematolOncolClin North Am.2018 Oct; 32(5):777-786. Doi:10.1016/j.hoc.2018.05.005. Epub 2018 Jul 25
Ari Ahn, ChanJeoung Park, Yong UkCho et al. Clinical, Laboratory, and Bone MarrowFindings of 31 PatientsWithWaldenströmMacroglobuliemia. Ann Lab Med.2020 May;40(3):193-200. Doi:10.3343/alm.2020.40.3.193
Jorge J Castillo, David F Moreno, Maria I Arbelaez et al. CXCR4 mutationsaffectpresentationandoutcomes in patientswithWaldenströmmacroglobulienemia : A systematicreview. ExpertRev Hematol.2019 Oct;12(10):873-881. Doi:10.1080/17474086.2019.1649132. Epub 2019 Jul 30.
AlessandraTedeschi, PaolaPicardi, Simone Ferrero et al. Bendamustineandrituximabcombination is safeandeffective as salvageregimen in Waldenströmmacroglobulinemia. LeukLymphoma. 2015;56(9):2637-42. Doi:10.3109/10428194.1012714. Epub 2015 Mar 14.
EstebanBraggio, CaseyPhilipsborn, Anne Novak. Molecularpathogenesis of Waldenstrom’smacroglobulinemia. Haematologica.2012 Sep; 97(99: 1281-90. Doi:103324/haematol.2012.068478. Epub 2012 Jul 6
Gayathri Ravi, PrashantKapoor. CurrentapproachtoWaldenströmmacroglobuliemia. CancerTreatRes Commun.2022:31:100527 doi: 10.1016/j.ctarc.2022.100527. Epub 2022 Feb 2.
G Dumas, S Merceron, L Zafrani et al. Hyperviscositysyndrome. RevMedInterne. 2015 Sep;36(9):588-95. Doi:10.1016/j.revmed.2015.02.005. Epub 2015 Mar 13
Alexander Grunenberg, ChristianBuske. How tomanageWaldenström’smacroglobulinemia in 2024. CancerTreat Rev.2024 Apr:125102715 doi:10.1016/j.ctrv.2024.102715
SaurabhZanwar, PrashantKapoor. Diagnosisand Risk Stratification in WaldenströmMacroglobulinemia. J NathComprCanc Netw.2024 Sep;22(7):e247024 doi:10.6004/jnccn.2024.7024
Giovanni Siconolfi, Francesca Vitali, Maria Ausilia. IgM Flare in Anti-MAG Neuropathy Post RituximabTreatment: A Cinical Case and a SystematicReview of theLiterature. Brain Sci.2024 Dec 22;14(12):1294.doi:10.3390/brainsci14121294.
